Early Go-to-Market Considerations for Cell & Gene Therapies

Sponsored content for Guidehouse by studioID

ON DEMAND WEBINAR
Duration: 1 hour

‚Äč
Progress in development of cell and gene therapies globally has the potential to transform standards of care for a range of diseases and address significant areas of unmet need in healthcare over the coming years.  The technology platforms of many of these drugs also offer the opportunity for curative efficacy and expansion for use in multiple indications. Innovation in gene therapy brings the potential for transforming patient care and obviating the need for chronic therapy through single-dose cures. 

Despite the potential long-term benefits of this new therapeutic modality, cell and gene therapy companies face several underappreciated challenges. In this webinar, we will review the early go-to-market considerations for cell and gene therapies:

  • Factors that influence adoption of cell and gene therapies and expansion of customer base
  • Customer-facing team roles and responsibilities vs. traditional pharmaceuticals
  • Key compliance considerations for customer-facing team interactions
 

SPEAKERS  

David Weiss
Partner
Life Sciences


Youbean Oak
Director
Life Sciences


Casey Horton
Director
Life Sciences

WATCH NOW

Field will not be visible to web visitor
Field will not be visible to web visitor
Field will not be visible to web visitor
Field will not be visible to web visitor
Field will not be visible to web visitor

Copyright 2020 Industry Dive | Privacy Policy | Terms of Use